MTOR and Parkinson disease: Serine and threonine kinases include various potential and validated therapeutic targets with key roles in human cancers (e.g., B-Raf [140], PIM kinases [141], aurora kinases [142], mammalian target of rapamycin (mTOR) [143]) and in the pathophysiology of neurodegenerative conditions including Alzheimer’s and Parkinson’s diseases (e.g., glycogen synthase kinase-3 (GSK-3) [144]).